CN118159565A - 结合gprc5d的抗体及其用途 - Google Patents

结合gprc5d的抗体及其用途 Download PDF

Info

Publication number
CN118159565A
CN118159565A CN202280073069.XA CN202280073069A CN118159565A CN 118159565 A CN118159565 A CN 118159565A CN 202280073069 A CN202280073069 A CN 202280073069A CN 118159565 A CN118159565 A CN 118159565A
Authority
CN
China
Prior art keywords
seq
amino acid
variable region
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280073069.XA
Other languages
English (en)
Chinese (zh)
Inventor
陆臻桢
王玉洁
彭双莉
张正平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN118159565A publication Critical patent/CN118159565A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280073069.XA 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途 Pending CN118159565A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111305149 2021-11-05
CN2021113051497 2021-11-05
PCT/CN2022/129803 WO2023078382A1 (zh) 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途

Publications (1)

Publication Number Publication Date
CN118159565A true CN118159565A (zh) 2024-06-07

Family

ID=86240662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280073069.XA Pending CN118159565A (zh) 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途

Country Status (6)

Country Link
EP (1) EP4428153A4 (https=)
JP (1) JP2024540148A (https=)
KR (1) KR20240099351A (https=)
CN (1) CN118159565A (https=)
TW (1) TW202334222A (https=)
WO (1) WO2023078382A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925229B (zh) * 2023-09-19 2023-12-15 南京驯鹿生物技术股份有限公司 一种靶向gprc5d的抗体及其应用
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
US12545726B1 (en) 2025-07-22 2026-02-10 Integral Molecular, Inc. Compositions and methods related to GPRC5D binding agents and variants thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017011932A8 (pt) * 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
SG11201907321TA (en) * 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
BR112021013824A2 (pt) * 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
CA3248329A1 (en) * 2019-07-31 2025-11-29 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d

Also Published As

Publication number Publication date
WO2023078382A1 (zh) 2023-05-11
EP4428153A4 (en) 2026-02-11
KR20240099351A (ko) 2024-06-28
EP4428153A1 (en) 2024-09-11
TW202334222A (zh) 2023-09-01
JP2024540148A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
JP7317272B2 (ja) Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
EP4428153A1 (en) Antibody binding to gprc5d and use thereof
CN112703013B (zh) Cd3抗原结合片段及其应用
US20250145705A1 (en) Gprc5d antibody and application thereof
US20240309087A1 (en) Anti-cd112r antibody and use thereof
TW202128765A (zh) 一種雙特異性抗體
CN113906053B (zh) 抗cea抗体及其应用
CN113840836B (zh) 抗结缔组织生长因子抗体及其应用
KR20250017233A (ko) 항-bdca2 항체 및 이의 용도
CN110606892B (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
AU2024260168A1 (en) Bispecific antibody targeting g protein-coupled receptor
WO2025035451A1 (zh) 抗cd93抗体、其组合物及用途
CN118556082A (zh) p95HER2抗体及其应用
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
WO2023178645A1 (zh) 靶向cd3的抗体及其应用
EP4663661A1 (en) Anti-cdh6 antibody and use thereof
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN115028722B (zh) 抗tslp抗体及其制备方法和用途
RU2817143C2 (ru) Антитело против cd79b, его антигенсвязывающий фрагмент и его фармацевтическое применение
AU2024331841A1 (en) Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof
KR20240099470A (ko) 항-cldn18.2 단일클론 항체 및 이의 응용
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
CN118894943A (zh) 靶向密蛋白的双特异性抗体
TW202313698A (zh) 抗ｍａｓｐ－２抗體及其用途
CN120988130A (zh) Siglec-15特异性单克隆抗体的制备及抗肿瘤效应

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination